CONSOLIDATED STATEMENT OF CASH FLOWS (USD $)	12 Months Ended		80 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
CASH FLOW FROM OPERATING ACTIVITIES
Net loss	$ (3,266,013)	$ (2,582,537)	$ (15,397,296)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization	160,625	185,271	1,137,359
Technology impairment	0	345,000	690,000
Common stock issued for services	0	18,500	318,500
Stock options and warrants	704,480	63,385	3,718,233
(Increase) decrease in assets
Prepaid drug product for testing	143,636	(42,000)	(51,364)
Other current assets	(21,542)	5,864	(64,117)
Increase (decrease) in liabilities
Accounts payable and accrued expenses	(34,346)	13,113	294,896
Net cash used in operating activities	(2,313,160)	(1,993,404)	(9,353,789)
CASH FLOW FROM INVESTING ACTIVITIES
Purchase of exclusive license - related party	0	(25,000)	(884,710)
Net cash used in investing activities	0	(25,000)	(884,710)
CASH FLOW FROM FINANCING ACTIVITIES
Proceeds from convertible notes	0	0	435,000
Cash repayment of convertible notes	0	0	(15,000)
Net proceeds from sale of common stock	5,330,946	1,600,198	13,370,331
Net cash from financing activities	5,330,946	1,600,198	13,790,331
NET INCREASE (DECREASE) IN CASH	3,017,786	(418,206)	3,551,832
Cash, beginning of period	534,046	952,252	0
Cash, end of period	3,551,832	534,046	3,551,832
Cash paid for
Interest	0	0	445
Income taxes	0	0	0
Non-cash financing activities
Common stock issued upon conversion of convertible notes	0	0	420,000
Placement Agent
Non-cash financing activities
Common stock issued	771,047	0	1,362,613
MD Anderson for License
Non-cash financing activities
Common stock issued	0	0	2,354,167
LPC
Non-cash financing activities
Common stock issued	$ 0	$ 1,750	$ 210,755